Zdrowie i gospodarka · 16.08.2000

Advisory Committees; Industry Representation

The Food and Drug Administration (FDA) is announcing its intention of adding one nonvoting representative of industry interests to the membership of its existing advisory committees that do not already have such nonvoting industry representation under the purview of the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER). Elsewhere in this issue of the Federal Register, FDA is publishing a notice to request nominations for nonvoting members of industry interests on public advisory committees.